Frank Gleeson
Founder chez SATELLOS BIOSCIENCE INC.
Fortune : 1 M $ au 31/03/2024
Profil
Frank Gleeson is the founder of Verio Therapeutics, Inc. (founded in 2008) and Satellos Bioscience, Inc. (founded in 2018).
He holds the title of President & Chief Executive Officer at Satellos Bioscience, Inc. from 2018 to present.
Mr. Gleeson is also the founder of Gleeson & Associates and Canadian Glycomics Network.
Currently, Mr. Gleeson is a Director at Mercal Capital Corp.
since 2015.
Previously, he served as the Chief Executive Officer of MDS Proteomics, Inc. from 1999 to 2003.
He also held the position of Chairman at Stem Cell Network and Director at Privacy Analytics, Inc. Mr. Gleeson completed his undergraduate degree and MBA at York University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SATELLOS BIOSCIENCE INC
3,48% | 07/09/2023 | 3 920 389 ( 3,48% ) | 1 M $ | 31/03/2024 |
Postes actifs de Frank Gleeson
| Sociétés | Poste | Début |
|---|---|---|
| SATELLOS BIOSCIENCE INC. | Founder | 01/01/2018 |
Mercal Capital Corp.
 Mercal Capital Corp. Financial ConglomeratesFinance Mercal Capital Corp. is a capital pool company, which engages in the identification and evaluation of potential acquisitions or businesses. The company was founded on August 31, 2015 and is headquartered in Ottawa, Canada. | Director/Board Member | 31/08/2015 |
| Gleeson & Associates | Founder | - |
Anciens postes connus de Frank Gleeson
| Sociétés | Poste | Fin |
|---|---|---|
| MDS Proteomics, Inc. | Chief Executive Officer | 01/01/2003 |
| Canadian Glycomics Network | Founder | - |
Verio Therapeutics, Inc.
 Verio Therapeutics, Inc. BiotechnologyHealth Technology Part of Fate Therapeutics, Inc., Verio Therapeutics, Inc. is a Canadian pharmaceutical company that manufactures products for activating endogenous stem cells. The private company is based in Ottawa, Canada. Verio Therapeutics was acquired by Fate Therapeutics, Inc. on April 08, 2010. The company was founded by Frank Gleeson, Michael Rudnicki. | Founder | - |
| Stem Cell Network | Chairman | - |
Satellos Bioscience, Inc. /Old/
 Satellos Bioscience, Inc. /Old/ BiotechnologyHealth Technology Satellos Bioscience, Inc. is a regenerative medicine company. The firm is dedicated to developing novel therapeutics that stimulates or restore muscle regeneration in severe disorders. The company focuses on the discovery that dysregulated muscle stem-cell polarity a process that balances replenishment of muscle stem cells and production of specialized tissue cells can lead to the inability of the body to properly repair and regenerate muscle throughout life. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which the firm has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. It applies its proprietary MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated. Satellos also maintains the rights to two clinical stage legacy assets as a result of the reverse takeover of iCo Therapeutics Inc.: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada. | Chief Executive Officer | - |
Formation de Frank Gleeson
| York University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
| MDS Proteomics, Inc. | Commercial Services |
Verio Therapeutics, Inc.
Verio Therapeutics, Inc. BiotechnologyHealth Technology Part of Fate Therapeutics, Inc., Verio Therapeutics, Inc. is a Canadian pharmaceutical company that manufactures products for activating endogenous stem cells. The private company is based in Ottawa, Canada. Verio Therapeutics was acquired by Fate Therapeutics, Inc. on April 08, 2010. The company was founded by Frank Gleeson, Michael Rudnicki. | Health Technology |
Privacy Analytics, Inc.
 Privacy Analytics, Inc. Packaged SoftwareTechnology Services Privacy Analytics, Inc. provides data anonymization software solutions for healthcare organizations, insurance and medical claims providers, and medical device manufacturers to safeguard and enable data for secondary purpose. The company was founded by Khaled El Emam in 2007 and is headquartered in Ottawa, Canada. | Technology Services |
Mercal Capital Corp.
Mercal Capital Corp. Financial ConglomeratesFinance Mercal Capital Corp. is a capital pool company, which engages in the identification and evaluation of potential acquisitions or businesses. The company was founded on August 31, 2015 and is headquartered in Ottawa, Canada. | Finance |
| Gleeson & Associates | |
Satellos Bioscience, Inc. /Old/
Satellos Bioscience, Inc. /Old/ BiotechnologyHealth Technology Satellos Bioscience, Inc. is a regenerative medicine company. The firm is dedicated to developing novel therapeutics that stimulates or restore muscle regeneration in severe disorders. The company focuses on the discovery that dysregulated muscle stem-cell polarity a process that balances replenishment of muscle stem cells and production of specialized tissue cells can lead to the inability of the body to properly repair and regenerate muscle throughout life. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which the firm has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. It applies its proprietary MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated. Satellos also maintains the rights to two clinical stage legacy assets as a result of the reverse takeover of iCo Therapeutics Inc.: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada. | Health Technology |
| Stem Cell Network | |
| Satellos Bioscience, Inc. | |
| Canadian Glycomics Network |
